Data coverage, completeness and provenance for AbbVie in the Stock Market API — Health Care · Drug Manufacturers - General.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees: 57,000 · Website: https://www.abbvie.com · Profile fields populated: 75%
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/ABBV/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 2025-12-31 | 30 | sec_edgar | ||||
| FY2024 | 2024-12-31 | 30 | sec_edgar | ||||
| FY2023 | 2023-12-31 | 30 | sec_edgar | ||||
| FY2022 | 2022-12-31 | 30 | sec_edgar | ||||
| FY2021 | 2021-12-31 | 30 | sec_edgar |
Every number on this page is one API call away. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/ABBV
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/ABBV/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/ABBV/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/ABBV/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/ABBV/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/ABBV
Free tier — instant API key. Built for AI agents.